Skip to content
Michael Best logo
Blurred abstract background with soft blue and white tones. Circular lights create a bokeh effect, conveying a calm and serene atmosphere.

Amanda Wait Steps into New Leadership Role at Washington, D.C. Office

Subscribe

Read

less than a minute

June 9, 2026

less than a minute

Related People

  • Amanda L. Wait

    Amanda L. Wait

    Managing Partner, D.C. Office

    Sub-Group Leader, Antitrust & Competition

    Amanda.Wait@michaelbest.com

    T 202.747.9560

Related Capabilities

  • Antitrust & Competition

You may also be interested in these

  • What Happens After a Trademark Settles? Key Provisions Businesses Often Overlook

    Reaching a settlement in a trademark dispute is a significant milestone, but it is rarely the end of the story. Many businesses focus on negotiating…

    Read

    Aug 13, 2026

  • FCC Expands Focus from Equipment Regulation to Supply Chain Governance for Connected Devices and Robotics

    FCC Expands Focus from Equipment Regulation to Supply Chain Governance for Connected Devices and Robotics

    The FCC has launched a new rulemaking that could significantly expand how connected devices are regulated in the United States. The proposal would strengthen restrictions on certain equipment and component parts associated with national security concerns, require additional supply-chain disclosures during the equipment authorization process, and increase oversight of entities involved in the sale and distribution of connected devices.

    Read

    Aug 13, 2026

  • FDA Proposes Mandatory GRAS Notification Framework for Human and Animal Food Substances

    FDA Proposes Mandatory GRAS Notification Framework for Human and Animal Food Substances

    On August 10, 2026, the U.S. Food and Drug Administration (“FDA” or “Agency”) proposed a new rule to require human and animal food manufacturers to notify the Agency of food substances purported to be generally recognized as safe (“GRAS”) under the conditions of their permitted use pursuant to section 321(s) of the Food, Drug and Cosmetic Act (“FD&C Act”) (21 U.S.C. § 321(s))).

    Read

    Aug 12, 2026

Subscribe

Slide Menu

Navigate through the site menu

Slide Search

Search through all content using keywords or phrases

Affiliates

Information

Practices

Industries

Stay in Touch

YouTube

LinkedIn

© 2026 Michael Best & Friedrich LLP

cping